Karolinska Development

Research note


Karolinska Development: Modus granted IND

Karolinska Development announced today that Modus Therapeutics has been granted Investigational New Drug (IND) status, paving the way for a phase I trial with a subcutaneous formulation of Sevuparin in the U.S. The announcement was in line with our expectations and will not affect our valuation of Karolinska Development.

Download our latest Research Report from 2018-08-15

Download full report icon-download